Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Baglivo

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Respiratory Disease|October 26, 2018
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experienceBiagio Ricciuti, Sara Baglivo, Andrea De Giglio, et al.
Oncoscience|January 17, 2015
Non-coding RNAs in lung cancerBiagio Ricciuti, Carmen Mecca, Lucio Crinò, et al.
Oncology and Therapy|July 24, 2020
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature ReviewGiulio Metro, Sara Baglivo, Riccardo Moretti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 25, 2017
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer PatientBiagio Ricciuti, Giulio Metro, Sara Baglivo, et al.
Clinical Drug Investigation|August 29, 2018
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer PatientGiulio Metro, Sara Baglivo, Annamaria Siggillino, et al.
Oncology and Therapy|July 24, 2020
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the LiteratureSara Baglivo, Vienna Ludovini, Riccardo Moretti, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidenceBiagio Ricciuti, Marta Brambilla, Giulio Metro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to CrizotinibBiagio Ricciuti, Luca Marcomigni, Giulio Metro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2018
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point MutationSara Baglivo, Biagio Ricciuti, Vienna Ludovini, et al.
Veterinary Microbiology|December 13, 2016
Single N-glycosylation site of bovine leukemia virus SU is involved in conformation and viral escapeGiorgia Rizzo, Katia Forti, Anna Serroni, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Respiratory Disease|October 26, 2018
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experienceBiagio Ricciuti, Sara Baglivo, Andrea De Giglio, et al.
Oncoscience|January 17, 2015
Non-coding RNAs in lung cancerBiagio Ricciuti, Carmen Mecca, Lucio Crinò, et al.
Oncology and Therapy|July 24, 2020
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature ReviewGiulio Metro, Sara Baglivo, Riccardo Moretti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 25, 2017
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer PatientBiagio Ricciuti, Giulio Metro, Sara Baglivo, et al.
Clinical Drug Investigation|August 29, 2018
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer PatientGiulio Metro, Sara Baglivo, Annamaria Siggillino, et al.
Oncology and Therapy|July 24, 2020
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the LiteratureSara Baglivo, Vienna Ludovini, Riccardo Moretti, et al.
Medical Oncology (Northwood, London, England)|April 27, 2017
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidenceBiagio Ricciuti, Marta Brambilla, Giulio Metro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to CrizotinibBiagio Ricciuti, Luca Marcomigni, Giulio Metro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2018
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point MutationSara Baglivo, Biagio Ricciuti, Vienna Ludovini, et al.
Veterinary Microbiology|December 13, 2016
Single N-glycosylation site of bovine leukemia virus SU is involved in conformation and viral escapeGiorgia Rizzo, Katia Forti, Anna Serroni, et al.
Pageof 5